ArticleBlood cancer journal2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis.Hematological oncology · 2023Pooled it
- COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).Journal of hematology & oncology · 2021Trial
- Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.Leukemia · 2026Article
- Recurrent left ventricular thrombus due to essential thrombocythemia complicated by COVID-19.Journal of cardiology cases · 2024Article
- Severe COVID-19 outcomes and hematological cancers: the clot thickens-are platelets the culprit?Translational cancer research · 2023Article
- SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms.Research and practice in thrombosis and haemostasis · 2023Article
- Semantic and Population Analysis of the Genetic Targets Related to COVID-19 and Its Association with Genes and Diseases.Advances in experimental medicine and biology · 2023Article
- Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis.Research and practice in thrombosis and haemostasis · 2022Article
- [Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms.Blood · 2022Article
- Surgical Complications in Myeloproliferative Neoplasm Patient with Essential Thrombocythemia: A Case Report.International medical case reports journal · 2022Article
- COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.Acta haematologica · 2022Review
- MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too.Hematology. American Society of Hematology. Education Program · 2021Review
- Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases.American journal of hematology · 2021Article
- COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis.BMJ case reports · 2021Article
- Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism.Blood cancer journal · 2021Article
- Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.American journal of hematology · 2021Article
- Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN.Leukemia research · 2021Article
- Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.Current hematologic malignancy reports · 2021Review
- Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 20 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.